Corrigendum to “New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases”

Key Points

• New drug therapies offer hope for treating primary adult glomerular diseases with reduced side effects.
• Promising outcomes arise from nonimmunosuppressive therapies, emphasizing their clinical potential in this field.
• Observational analysis of emerging therapies evaluates their efficacy in improving patient outcomes and overall health.
• Validating nonimmunosuppressive options could transform treatment standards, but broader clinical trials are needed.